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Abstract
Background:  There is currently no standard adjuvant therapy for patients with curatively
resected extrahepatic biliary tract cancer (EHBTC). The aim of this study was to analyze the clinical
features and outcomes between patients undergoing adjuvant concurrent chemoradiation therapy
(CCRT) alone and those undergoing CCRT followed by adjuvant chemotherapy after curative
resection.
Methods: We included 120 patients with EHBTC who underwent radical resection and then
received adjuvant CCRT with or without further adjuvant chemotherapy between 2000 and 2006
at Seoul National University Hospital.
Results: Out of 120 patients, 30 received CCRT alone, and 90 received CCRT followed by
adjuvant chemotherapy. Baseline characteristics were comparable between the two groups. Three-
year disease-free survival (DFS) rates for CCRT alone and CCRT followed by adjuvant
chemotherapy were 26.6% and 45.2% (p = 0.04), respectively, and 3-year overall survival (OS) rates
were 30.8% and 62.6% (p < 0.01), respectively. CCRT followed by adjuvant chemotherapy showed
longer survival than did CCRT alone, especially in R1 resection (microscopically positive margins)
or negative lymph node.
Conclusion:  Adjuvant CCRT followed by adjuvant chemotherapy prolonged DFS and OS,
compared with CCRT alone in patients with curatively resected EHBTC. Adjuvant chemotherapy
deserves to consider after adjuvant CCRT. In the future, a randomized prospective study will be
needed, with the objective of investigating the role of adjuvant chemotherapy.
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Background
Extrahepatic biliary tract cancer (EHBTC) is a rare malig-
nant tumor, accounting for 7500 new cases and 3300
deaths in the United States in 2005 [1]. These tumors arise
from the epithelial cells of the extrahepatic bile ducts and
can be divided into hilar, distal bile duct, and gallbladder
origin. The type of resection and prognosis vary with ana-
tomic location [2]. Complete surgical resection with his-
tologically negative surgical margins has been reported to
be the most important factor for the curative treatment of
patients with EHBTC [3]. However, many patients are not
suitable for curative surgery on presentation, and the fre-
quency of positive resection margins has been reported to
be anywhere from 9% to 74% after surgical resection [4].
In addition, loco-regional failure occurs in more than half
of patients, even after complete resection [5,6]. Because of
frequent local relapses and distant metastasis after cura-
tive resection, a treatment approach combining local and
systemic adjuvant treatment is of interest in patients with
EHBTC. The role of adjuvant treatment has not yet been
established. Previous studies evaluating adjuvant radia-
tion therapy (RT) with a variety of methods have led to
conflicting results [7-10], and no large randomized trials
of adjuvant concurrent chemoradiation therapy (CCRT)
have been performed. However, several retrospective
studies and phase II studies have reported that CCRT
might have some benefits for local control, especially in
the management of patients with positive microscopic
margins and positive lymph nodes [10-12]. However,
most of these studies have included a mixture of patients
with complete and incomplete resection and have not
evaluated the role of adjuvant chemotherapy after adju-
vant CCRT.
Chemotherapy as a treatment modality for EHBTC has
been shown to have low efficacy, and the role of adjuvant
chemotherapy has not yet been thoroughly studied. A sin-
gle randomized trial reported that although it did not
reach the level of statistical significance, the difference in
5-year survival rates between patients who received and
did not receive chemotherapy following curative resection
was of large magnitude (41% versus 28%) [13]. Further-
more, in cases of advanced cholangiocarcinoma, a small
randomized trial assigning 90 patients with advanced
pancreatic or biliary cancer (37 with bile duct cancer) to
5-fluorouracil (5-FU)-based systemic chemotherapy or
best supportive care alone suggested the benefit of chem-
otherapy over best supportive care alone [14]. These
results suggested the possibility that 5-FU based chemo-
therapy could play some role in the treatment of biliary
tract cancer, despite low efficacy.
Previous series have reported that distant metastasis of
EHBTC occurs as frequently as local recurrence after cura-
tive resection [5,6]. Therefore, with regard to control of
distant metastasis, as well as local control, adjuvant CCRT
leaves something to be desired. There is still the question
of whether further adjuvant chemotherapy is needed after
CCRT. However, little is yet known concerning the use of
CCRT alone or CCRT followed by adjuvant chemotherapy
as adjuvant treatment after curative surgical resection.
The purpose of this retrospective study was to compare the
clinical features, disease free survival (DFS), and overall
survival (OS) between patients undergoing adjuvant
CCRT alone and those undergoing CCRT followed by
adjuvant chemotherapy and to evaluate prognostic factors
and patterns of recurrence.
Methods
Patients and treatments
Of the 234 patients who had undergone radical resection
at Seoul National University Hospital from January 2000
to December 2006, we collected 120 cases of invasive,
non-metastatic EHBTC treated with adjuvant CCRT with
or without further adjuvant chemotherapy, while 114
patients was excluded because of following causes such as
no adjuvant treatment (n = 88) or adjuvant RT only (n =
12) or follow-up loss (n = 14). A total of 120 cases met the
following inclusion criteria: histologically confirmed,
non-metastatic adenocarcinoma of extrahepatic biliary
tract except for gallbladder and periampullary cancer. This
study was reviewed and approved by the Institutional
Review Board of the Seoul National University Hospital.
After Institutional Review Board approval, patients' medi-
cal records were reviewed for the following characteristics:
age, gender, tumor markers, surgical procedures, histo-
logic features, stage, resection margin status, radiation
treatment, chemotherapy treatment, pattern of recur-
rence, and survival. As tumor marker, the preoperative car-
bohydrate antigen 19-9(CA19-9) levels were measured in
most patients.
Resection procedures were classified into 4 groups: pan-
creaticoduodenectomy (PD) with or without pylorus
preservation and segmental bile duct resection with or
without hepatectomy. Lymph node dissection was done
in all but 4 patients. Four patients without lymph node
dissection belonged to CCRT followed by adjuvant chem-
otherapy group. Resection type determination was
dependent on the location and extent of the tumor. All
patients underwent surgical resection with the intent to
cure. If a microscopic free margin could not be obtained,
additional resection was attempted. But, final pathologic
results reported that there were positive resection margins
in 41 patients. Therefore, 41 patients had undergone R1
resection, despite additional resection. In this classifica-
tion, we excluded all cases that underwent resection for
palliation with gross residual tumor (R2 resection).BMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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All pathology specimens were reviewed to determine the
primary pathologic diagnosis and extent of disease.
Patients were staged, based on criteria from the American
Joint Committee on Cancer (AJCC), 6th edition [15].
All patients received concurrent 5-FU chemotherapy and
external beam RT. 5-FU was administered at a dose of 500
mg/m2 on D1, 2, 3 and on D28, 29, 30 along with 4000-
5400 cGy of external beam radiation. The radiation fields
were primary tumor bed and regional lymph node. The
102 patients received 40 Gy of radiation delivered as a
split course of 20 Gy in 10 fractions over 2 weeks with a 2-
week break between courses. The remaining 18 patients
received 5040-5400 cGy of radiation without splitting
course. All but 2 patients started adjuvant therapy within
post-operative 3 months. Two patients who received
delayed treatment due to wound problem belonged to
CCRT followed by adjuvant chemotherapy group. Of 120
patients, 117 patients completed whole course of CCRT.
Two patients of 3 patients who did not complete whole
course were in CCRT followed by adjuvant chemotherapy
group and one patient was in CCRT alone group. Also,
there was no significant difference in radiation dose and
method between CCRT alone and CCRT followed by
adjuvant chemotherapy groups. Patients received one
fraction per day, 5 days per week. The median dose per
fraction was 200 cGy (range, 180-240 cGy). CCRT began
a mean of 6.9 weeks after surgery (range, 4.4-14.9 weeks).
The mean duration of RT was 5.8 weeks (range, 4.0-7.1
weeks). No patients died within 6 months after adjuvant
CCRT.
Ninety patients received further 5-FU based adjuvant
chemotherapy for 6-12 months. Adjuvant chemotherapy
regimens were comprised of various combinations of 5-
FU. Forty-four patients received monthly 5-FU (500 mg/
m2 per day for 5 days) infusion alone; 29 received 5-FU
(375 mg/m2 per day for 5 days) and leucovorin (20 mg/
m2 per day for 5 days); 16 received single oral 5-FU deriv-
atives such as uracil-tegafur, capecitabine and TS-1; 1
received 5-FU, leucovorin, and mitomycin C. Medical
oncologist gave the treatment option about additional
chemotherapy after adjuvant CCRT to patient. Whether
patient received additional adjuvant chemotherapy or not
was dependent on patient's will. The duration of adjuvant
chemotherapy depended on physician's decision.
Statistical analysis
The primary clinical endpoints for this retrospective study
were DFS and OS. Survival data were processed using the
Kaplan-Meier method and were compared using the log-
rank test and Cox proportional hazards regression. A P
value of less than 0.05 was considered statistically signifi-
cant. To identify differences in baseline characteristics
between treatment groups, the Chi-square test and
Fisher's exact test were used and continuous variables
were compared using the Student t test.
Results
Patient characteristics and clinical outcomes
Patient and disease characteristics are summarized in
Table 1. A total of 120 patients met the inclusion criteria.
There were 89 men (74.2%). The median age was 62.4
years (range, 24.2-87.0 years). The median tumor size was
2.5 cm (range, 1.0-6.5 cm). Median numbers of dissected
lymph nodes were 11.5 (range, 1-40). Positive lymph
nodes were found in 35.8% of cases. Seventy-nine
(65.8%) patients received R0 resection (pathologically
negative margins), and 41 (34.2%) patients received R1
resection (microscopically positive margins). Twenty
(16.7%) patients had well-differentiated tumors, 11
(9.2%) had at least a component of poorly differentiated
tumor, and the remaining 74.1% of specimens were mod-
erately differentiated. By the 2002 AJCC TNM staging sys-
tem, 40 patients were stage I, 64 were stage II, and 16 were
stage III; no patients were stage IV [15].
The median follow-up duration was 21.4 months. Death
occurred in 48 of 120 patients (40.0%) during the follow-
up period, all due to disease-related complications. The
median DFS was 25.0 months, with a 3-year DFS of
40.8%. The median overall survival was 55.8 months,
with a 3-year OS of 54.8%.
Out of 120 patients, 30 received CCRT alone, and 90
received CCRT followed by adjuvant chemotherapy.
Median follow-up periods for the CCRT alone and CCRT
followed by adjuvant chemotherapy groups were 16.6
and 23.6 months, respectively and there was no signifi-
cant difference between both groups. Thirty patients who
received CCRT alone showed comparatively even distribu-
tion annually. Baseline characteristics were comparable
between the two groups, including age, gender, perform-
ance status, T status, nodal status, resection margin, tumor
location, and other pathologic parameters (Table 1).
Median numbers of dissected lymph nodes for the CCRT
alone and CCRT followed by adjuvant chemotherapy
groups were 12.5 (range, 1-29) and 11.0 (range, 1-40),
respectively and there was no significant difference
between both groups (p = 0.52). Three-year DFS rates for
the CCRT alone and CCRT followed by adjuvant chemo-
therapy groups were 26.6% and 45.2%, respectively, with
median DFS of 17.7 and 29.9 months (p = 0.04), respec-
tively (Figure 1(a)). Three-year OS rates for the two groups
were 30.8% and 62.6%, with median OS of 22.1 months
and an unavailable median OS (p < 0.01), respectively
(Figure 1(b)).
For subgroups with R1 resection (Figure 2(a)) or negative
nodal status (Figure 2(b)), CCRT followed by adjuvant
chemotherapy led to longer DFS and OS than did CCRTBMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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Table 1: Clinicopathologic characteristics of study population
Total patients CCRT CCRT followed by adjuvant chemotherapy P+ value
Case 120 30 90
Median age, years (range) 62.4 (24.2~87.0) 63.4 (24.2~74.4) 62.1 (38.8~87.0) 0.87
Men (%) 89 (74.2) 20 (66.7) 69 (76.7) 0.25
Performance ECOG 0-1 111 (92.5) 28 (93.3) 83 (92.2) 0.73
ECOG 2 9 (7.5) 2 (6.7) 7 (7.8)
T stage (%) T1 20 (16.7) 4 (13.3) 16 (17.8) 0.53
T2 33 (27.5) 6 (20.0) 27 (30.0)
T3 51 (42.5) 16 (53.3) 35 (38.9)
T4 16 (13.3) 4 (13.3) 12 (13.3)
N stage (%) N0 77 (64.2) 18 (60.0) 59 (65.6) 0.58
N1 43 (35.8) 12 (40.0) 31 (34.4)
Stage (%) IA 13 (10.8) 2 (6.7) 11 (12.2) 0.73
IB 27 (22.5) 5 (16.7) 22 (24.4)
IIA 29 (24.2) 9 (30.0) 20 (22.2)
IIB 35 (29.2) 10 (33.3) 25 (27.8)
III 16 (13.3) 4 (13.3) 12 (13.3)
RM status (%) Negative 79 (65.8) 19 (63.3) 60 (66.7) 0.74
Positive 41 (34.2) 11 (36.7) 30 (33.3)
CA 19-9 (%) ≤ 60 U/ml 57 (47.5) 17 (56.7) 40 (44.4) 0.27
> 60 62 (51.7) 13 (43.3) 49 (54.4)
Tumor location (%) Proximal 59 (49.2) 13 (43.3) 46 (51.1) 0.52
Distal 55 (45.8) 15 (50.0) 40 (44.4)
Histologic grade (%) WD/MD 107 (89.2) 29 (96.7) 78 (86.7) 0.29
PD 11 (9.2) 1 (3.3) 10 (11.1)
Recurrence (%) Local 22 (32.4) 5 (26.3) 17 (34.7) 0.51
Systemic 46 (67.6) 14 (73.7) 32 (65.3)
+Statistical value between CCRT and CCRT followed by adjuvant chemotherapy
ECOG, Eastern Cooperative Oncology Group; RM, resection margin; WD, well differentiated; MD, moderate differentiated; PD, poor 
differentiated; CCRT, concurrent chemoradiation therapy.
Disease-free survival and overall survival by concurrent chemoradiation therapy (CCRT) alone and CCRT followed by adjuvant  chemotherapy Figure 1
Disease-free survival and overall survival by concurrent chemoradiation therapy (CCRT) alone and CCRT fol-
lowed by adjuvant chemotherapy. Patients treated with CCRT followed by adjuvant chemotherapy had better disease-
free survival (a) and overall survival (b) compared to those treated with CCRT alone.BMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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alone. This same pattern was not true for patients with R0
resection or positive lymph nodes. Also, CCRT followed
by adjuvant chemotherapy did not have more clinical
benefit than CCRT alone in patients with T1/2 stage for
DFS (p = 0.43) and OS (p = 0.50), while CCRT followed
by adjuvant chemotherapy showed longer DFS (p = 0.04)
and OS (p < 0.01) than CCRT alone in patients with T3/4
stage.
We analyzed subgroups according to tumor location and
tumor marker CA 19-9 levels. Tumor location was classi-
fied as proximal or distal, with the cystic duct as a refer-
ence point, and CA 19-9 levels were classified as median
values. For proximal tumors, CCRT followed by adjuvant
chemotherapy was superior to CCRT alone with regard to
DFS (p < 0.01) and OS (p < 0.01). For distal tumors, there
was no difference between the groups with regard to DFS
and OS. Our study also showed that CCRT followed by
adjuvant chemotherapy was more effective than CCRT
alone for CA 19-9 levels elevated above the median value.
Pattern of failure
The site of relapse was evaluated for all patients. A total of
68 failures (56.6%) were observed. Loco-regional failures
occurred in 22 patients (18.3%), and distant failures
occurred in 46 patients (38.3%). Local relapse occurred
Disease-free survival and overall survival of R1 resection (a) and negative nodal groups (b) by concurrent chemoradiation ther- apy (CCRT) alone and CCRT followed by adjuvant chemotherapy Figure 2
Disease-free survival and overall survival of R1 resection (a) and negative nodal groups (b) by concurrent 
chemoradiation therapy (CCRT) alone and CCRT followed by adjuvant chemotherapy. The patients treated with 
CCRT followed by adjuvant chemotherapy showed better clinical outcomes than those treated with CCRT alone, especially in 
R1 resection or negative nodal group.BMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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simultaneously in 23 (50.0%) of 46 patients with distant
metastasis. From a calculation of the number of metastatic
sites by overlapping metastatic sites, metastatic sites
included the liver in 28 patients, peritoneal cavity in 14,
lung in 3, adrenal gland in 2, abdominal wall in 2, and in
other areas in 2. There was no difference in the recurrence
pattern between the CCRT alone group and the CCRT fol-
lowed by adjuvant chemotherapy group (p = 0.51).
Prognostic factors
On univariate analysis, significant factors for OS included
elevated CA 19-9 (p = 0.048) and pattern of adjuvant
treatment (p = 0.004). Histologic grade was not statisti-
cally significant, but high histologic grade tended to con-
fer a poor prognosis (p = 0.065). CA 19-9 (p = 0.011),
lymph node status (p = 0.005), pattern of adjuvant treat-
ment (p = 0.038), and histologic grade (p = 0.029) were
significant for DFS (Table 2).
On multivariate analysis, four variables for predicting sur-
vival were incorporated: CA 19-9, N stage, use of adjuvant
chemotherapy and histologic grade. Of these variables,
elevated CA 19-9 level, pattern of adjuvant treatment, and
histologic grade were found to be significant factors for
DFS (Table 3) and OS.
Toxicity
Adverse effects were ranked according to the common tox-
icity criteria of the National Cancer Institute (NCI). In
general, treatment was well tolerated. The most common
acute side effects were grade 2 nausea and vomiting
(43.3%). Of the 90 patients who received adjuvant chem-
otherapy, 16 patients (17.7%) experienced grade 2 hema-
tologic toxicity, and 6 patients (6.7%) experienced grade
3 hematologic toxicity. Grade 1 or 2 stomatitis was
recorded in 13 patients (14.4%). Grade 2 hand-foot syn-
drome developed in one patient.
Discussion
Surgical resection is the only curative treatment for biliary
tract cancer. Resectability is considered an important
prognostic factor in many studies [16-18]. The resectabil-
ity rate of EHBTC has been reported to range between
10% and 47%, despite differences in resectability rate
according to tumor location [19-22]. Following complete
surgical resection, the most common relapse pattern is
loco-regional, with subsequent bile duct obstruction, liver
failure, and recurrent sepsis [5]. Therefore, in considering
postoperative local control, many studies have reported
the role of RT with or without chemotherapy. However,
there have been conflicting results for the role of adjuvant
RT after radical resection, especially R0 resection, and no
randomized controlled trial has resolved the inconsistent
findings.
Many retrospective studies and small phase II studies have
shown a benefit with adjuvant RT, especially for the con-
trol of microscopic residual tumor [8-10,12,23]. Oh et al.
Table 2: Univariate analysis of clinicopathologic factors associated with disease-free survival and overall survival
No. of patients (%) P value (OS) P value (DFS)
Age > 60 68 (56.7) 0.506 0.849
≤ 60 52 (43.3)
Sex M 89 (74.2) 0.321 0.443
F 31 (25.8)
T stage T1/T2 53 (44.2) 0.679 0.645
T3/T4 67 (55.8)
N stage N0 77 (64.2) 0.223 0.005
N1 43 (35.8)
Stage I 40 (33.3) 0.902 0.129
II/III 80 (66.7)
Resection margin Negative 79 (65.8) 0.811 0.700
Positive 41 (34.2)
CA 19-9 ≤ 60 U/ml 57 (47.5) 0.048 0.011
> 60 U/mL 62 (51.7)
Tumor location Proximal 59 (49.2) 0.207 0.224
Distal 55 (45.8)
Histologic grade WD/MD 107 (89.2) 0.065 0.029
PD 11 (9.2)
Angiolymphatic invasion Yes 38 (31.7) 0.789 0.576
No 62 (51.7)
Perineural invasion Yes 87 (72.5) 0.419 0.098
No 24 (24.0)
Adjuvant treatment CCRT 30 (25.0) 0.004 0.038
CCRT + AC 90 (75.0)
OS, overall survival; DFS, disease-free survival; WD, well differentiated; MD, moderate differentiated; PD, poor differentiated; CCRT, concurrent 
chemoradiation therapy; AC, adjuvant chemotherapy.BMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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showed that adjuvant RT was useful in patients with
microscopic residual tumor [23]. A recent study by Todor-
oki et al. revealed that an adjuvant RT group had a higher
5-year survival rate (33.9%) than a group with resection
alone (13.5%), especially for patients with R1 resection
[12]. Also, Todoroki et al. reported the efficient eradica-
tion of microscopic local-regional tumor residue by add-
ing intraoperative RT to postoperative RT appeared to
result in prolonging survival by preventing distant metas-
tasis. Kim et al. reported the results of adjuvant CCRT with
and without adjuvant chemotherapy after radical resec-
tion in 84 patients with EHBTC [10]. In this study,
patients with microscopically positive resection margins
had a 5-year survival rate of 35%, and patients with micro-
scopically negative margins had a 5-year survival rate of
36%. This result suggested that despite no significant dif-
ference between the survival rates of the two groups, adju-
vant CCRT might play a role in patients with R1 resection.
Serafini et al. reported that median survival (41 months)
of patients with distal cholangiocarinoma receiving adju-
vant CCRT was significantly longer than that (25 months)
of patients not receiving adjuvant CCRT [11].
However, some studies have shown no benefit with adju-
vant RT in patients with EHBTC [2,7,24]. One prospective
study showed that surgical resection and RT in 50 patients
with perihilar tumors had no beneficial effect on survival
or quality of survival, although the fact that lymph node
evaluation was done in only 15 patients and no informa-
tion was gathered concerning T stage might reduce the
value of this prospective study [24]. Another small rand-
omized trial conducted in 207 patients with pancreatic or
periampullary malignancies failed to demonstrate a sur-
vival benefit for postoperative CCRT compared to surgery
alone [25], but the study was limited in that there were
fewer than 100 patients with periampullary cancers in this
trial, only some of which were of biliary origin. Twenty
percent of the patients in the treatment arm received no
adjuvant treatment because of postoperative complica-
tions or refusal.
Many hospitals have carried out CCRT as a practical treat-
ment option for patients with positive resection margins,
advanced T stage, or lymph node metastasis, although this
adjuvant treatment has not been demonstrated to be the
standard through randomized prospective study. Our
institution recommended adjuvant CCRT with or without
further adjuvant chemotherapy in some patients, based
on assumptions that loco-regional disease recurrence rates
are high and that improving loco-regional disease control
improves survival [7,12,26,27].
In this study, we reviewed 120 patients treated with adju-
vant treatment after R0 and R1 resection. Adjuvant CCRT
followed by adjuvant chemotherapy was significantly dif-
ferent with regard to DFS (p = 0.04) and OS (p < 0.01),
compared with CCRT alone. Patients that had either R1
resection or negative node status experienced more bene-
fits with CCRT followed by adjuvant chemotherapy. How-
ever, there was no significant difference in DFS and OS
between the CCRT alone and CCRT followed by adjuvant
chemotherapy groups for patients with R0 resection (p =
0.43, p = 0.15) or positive nodal status (p = 0.96, p =
0.23). The local failure rate was not different between the
CCRT alone (5 out of 30, 16.7%) and CCRT followed by
adjuvant chemotherapy (17 out of 90, 18.9%) groups.
Furthermore, the rate of distant metastasis was no differ-
ent between the CCRT alone (14 out of 30, 46.7%) and
CCRT followed by adjuvant chemotherapy (31 out of 90,
34.4%) groups. However, even though it was not statisti-
cally significant, CCRT followed by adjuvant chemother-
apy showed a tendency to prevent the development of
distant metastasis.
The results of our study showed that adjuvant CCRT might
be as effective in controlling microscopic residual tumor
as some previous studies have suggested, and there is the
possibility that further adjuvant chemotherapy could
reduce recurrence, especially systemic relapse, after CCRT
for patients with R1 resection. The loco-regional relapse
rate in our study was lower than that seen in previous
studies [5], because we classified a concomitant relapse at
loco-regional and distant sites as a systemic recurrence.
Although tumor location had no prognostic impact on
survival on univariate analysis in this study, patients with
Table 3: Multivariate analysis of clinicopathologic factors associated with disease-free survival
Variable P value Hazard ratio 95% CI
CA 19-9
(≤ 60 U/mL versus 60 > U/mL)
< 0.01 0.434 0.256 - 0.735
N stage 0.17 1.430 0.862 - 2.374
Histologic grade
(WD/MD versus PD)
0.01 0.345 0.162 - 0.733
CCRT alone versus
CCRT followed by adjuvant chemotherapy
0.01 0.429 0.239 - 0.770
WD, well differentiated; MD, moderate differentiated; PD, poor differentiated;
CCRT, concurrent chemoradiation therapy; CI, confidence interval.BMC Cancer 2009, 9:345 http://www.biomedcentral.com/1471-2407/9/345
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proximal EHBTC had better DFS and OS when treated
with CCRT followed by adjuvant chemotherapy. Patients
with distal EHBTC had no significant difference in sur-
vival when treated with CCRT alone or CCRT followed by
adjuvant chemotherapy.
Radiosensitization with cytotoxic agents has become
standard practice in the treatment of gastrointestinal
malignancies. 5-FU is known to be one of the most active
single agents in biliary tract cancer and is frequently used
in a combined modality approach because of its potential
radiosensitization effect. In general, these regimens are
well tolerated. However, the number of patients treated
with adjuvant RT alone in this study was small, and direct
comparison was not done.
Adjuvant chemotherapy after adjuvant CCRT has not been
routinely applied to patients with EHBTC and has not yet
been studied. The role of further adjuvant chemotherapy
remains unclear. 5-FU and gemcitabine-based regimens
are used universally and are known to be active in meta-
static EHBTC. 5-FU-based regimens include 5-FU alone, 5-
FU in combination with other agents, uracil-tegafur,
capecitabine, and S-1. In the palliative setting, these 5-FU-
based chemotherapy yields response rates of 10-40% and
overall survival somewhat better than best supportive
therapy alone [14,28-30]. On the basis of this back-
ground, the group in our study treated with adjuvant
chemotherapy showed a longer DFS and OS than did the
group without adjuvant chemotherapy, especially for
patients with R1 resection, patients with more than T3 or
patients with negative nodal status. No beneficial effects
of further adjuvant chemotherapy were shown in the
lower risk patients, such as those with R0 resection or
those who were less than T2. Furthermore, there was no
significant difference in survival between the two groups
with positive nodal status, despite the assumption that
adjuvant chemotherapy would reduce local and systemic
relapse and result in a survival advantage. The implica-
tions of these results should be considered. First, current
nodal status simply classifies N0 and N1, regardless of the
number and location of involved nodes, and cannot
reflect the exact extent of disease. Second, some incom-
plete lymph node dissections could have been done.
Third, the efficacy of 5-FU was still low, in spite of its
active agency in biliary tract cancer. This suggests a need
for intensification of adjuvant treatment through the use
of novel agents in cases with node metastasis.
Prognostic factors such as extent of surgical procedure, T
stage, nodal status, tumor location, and others have been
identified in many reports [3,9,10,12,22,24,30]. In our
study, the pattern of adjuvant treatment, elevated CA 19-
9 level, and histologic grade were significant prognostic
factors for DFS and OS on multivariate analysis.
By its nature, our study was subject to several limitations.
First, the study is a retrospective series, which could have
shortcomings such as selection bias. Second, adjuvant
chemotherapy was not identical. We did not consider fac-
tors such as differences in efficacy between 5-FU alone
and combination 5-FU therapy or duration of chemother-
apy. The effect of these differences on the study outcome
is unknown. Third, as a small portion of patients was
included in subgroup analysis as R1 resection, our results
should be interpreted with caution.
Despite these shortcomings, our study is valuable for
many reasons. First, this study is one of largest reports to
date comparing CCRT and CCRT followed by adjuvant
chemotherapy. Second, unlike previous reports, the pop-
ulation in our study was characterized by a homogeneous
disease representation. Previous studies looked at a com-
bination of extrahepatic cholangiocarcinoma and other
diseases, such as gallbladder and periampullary cancer.
They also looked at diverse disease status, including R0,
R1, and R2 resection, whereas the current study enrolled
only patients with extrahepatic cholangiocarcinoma and a
history of curatively radical surgery, such as R0 or R1
resection, and excluded patients with gallbladder cancer
or intrahepatic cholangiocarcinoma. Therefore, in our
study, CCRT with or without adjuvant chemotherapy was
done only as an adjuvant treatment, not as a palliative
treatment.
Conclusion
Our work supports the superiority of CCRT followed by
adjuvant chemotherapy over CCRT alone for promoting
survival in curatively resectable EHBTC. Our study
showed that the recurrence rate is as high as 50 percent,
even if radical surgery and adjuvant treatment are
employed, and this provides a strong rationale for the use
of adjuvant chemotherapy after CCRT in subgroup
patients, especially with R1 resection or with negative
lymph node. In the future, a prospective study will be
needed, with the objective of investigating the role of
adjuvant chemotherapy and other active agents.
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